Deciphera Pharmaceuticals to Present at the Canaccord Genuity 36th Annual Growth Conference

Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Michael D. Taylor, Ph.D., Deciphera’s President and Chief Executive Officer, will present a corporate update at the upcoming Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 3:30 p.m. ET in Boston, Massachusetts.

About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera’s unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera’s business strategy is to advance its drug candidates for genetically-defined cancers and cancers that target the tumor microenvironment.

Contacts:
Michael D. Taylor, Ph.D., Deciphera Pharmaceuticals LLC
mtaylor@deciphera.com
781-209-6411

Media:
Gina Nugent, The Yates Network
gina@theyatesnetwork.com
617-460-3579